Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

Current Atherosclerosis Reports

Volumn 16, Issue 12, 2014, Pages 1-8

  Johnston, Craig A ^a   Moreno, Jennette P ^a   Foreyt, John P ^b  

^a U S DEPARTMENT OF AGRICULTURE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Lifestyle intervention; Look AHEAD trial; Risk factors; Type 2 diabetes; Weight loss

Indexed keywords

BIOLOGICAL MARKER;

BLOOD PRESSURE; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; DYSLIPIDEMIA; EXERCISE INTENSITY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVENTIVE HEALTH SERVICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK REDUCTION; SLEEP DISORDERED BREATHING; WEIGHT REDUCTION; ADULT; AGED; BODY MASS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; INTERVENTION STUDY; LIFESTYLE; MALE; MIDDLE AGED; MORTALITY; OBESITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INTERVENTION STUDIES; LIFE STYLE; MALE; MIDDLE AGED; MORTALITY; OBESITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84910623058     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0457-6     Document Type: Review

References (90)

1. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96(9):3248–50.
2. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Med Clin North Am. 2011;95(5):919–37.
3. Schelbert KB. Comorbidities of obesity. Prim Care. 2009;36(2):271–85.
4. Smith Jr SC, Collins A, Ferrari R, et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). J Am Coll Cardiol. 2012;60(22):2343–8.
5. World Health Organization. Cardiovascular disease: global atlas on cardiovascular disease prevention and control. Geneva, Switzerland: WHO; 2012
6. International Diabetes Federation. Diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013
7. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996;93(7):1372–9.
8. Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ. 1997;314(7090):1311–7.
9. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA. 1995;273(6):461–5.
10. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141(12):1117–27.
11. Spataro JA, Dyer AR, Stamler J, Shekelle RB, Greenlund K, Garside D. Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. J Clin Epidemiol. 1996;49(8):849–57.
12. Harris TB, Launer LJ, Madans J, Feldman JJ. Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. BMJ. 1997;314(7097):1791–4.
13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13.
14. Eisenstein EL, Shaw LK, Nelson CL, Anstrom KJ, Hakim Z, Mark DB. Obesity and long-term clinical and economic outcomes in coronary artery disease patients. Obes Res. 2002;10(2):83–91.
15. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292(20):2471–7.
16. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–72.
17. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145–51.
18. International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012. Accessed August 20, 2014.
19. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31 Suppl 1:S12–54.
20. Laddu D, Dow C, Hingle M, Thomson C, Going S. A review of evidence-based strategies to treat obesity in adults. Nutr Clin Pract. 2011;26(5):512–25.
21. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.
22. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.
23. Perri MG. Effects of behavioral treatment on long-term weight loss: lessons learned from the Look AHEAD trial. Obesity (Silver Spring). 2014;22(1):3–4.
24. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring). 2014;22(1):5–13. This study produced long-term clinically meaningful weight loss in patients with type 2 diabetes. The lifestyle modification strategies used in this study may be utilized in the management of other comorbidities of obesity.
25. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24(5):610–28.
26. Brancati FL, Evans M, Furberg CD, et al. Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials. 2012;9(1):113–24.
27. Bray G, Gregg E, Haffner S, et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Vasc Dis Res. 2006;3(3):202–15.
28. Wesche-Thobaben JA. The development and description of the comparison group in the Look AHEAD trial. Clin Trials. 2011;8(3):320–9.
29. Look AHEAD Research Group, Wadden TA, West DS, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14(5):737–52.
30. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–26.
31. Jakicic JM, Jaramillo SA, Balasubramanyam A, et al. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond). 2009;33(3):305–16.
32. Foy CG, Lewis CE, Hairston KG, et al. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity (Silver Spring). 2011;19(1):83–93.
33. Stewart TM, Bachand AR, Han H, Ryan DH, Bray GA, Williamson DA. Body image changes associated with participation in an intensive lifestyle weight loss intervention. Obesity (Silver Spring). 2011;19(6):1290–5.
34. Williamson DA, Rejeski J, Lang W, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163–71.
35. Look AHEAD Research Group. Effect of a long-term behavioral weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD randomized clinical trial. Lancet. in press. Chronic kidney disease is a risk factor for heart failure. Participants in the ILI reduced their risk of CKD by 31 % compared to participants in the DSE, which may eventually lead to reduced CVD mortality. It is possible that the Look AHEAD intervention was ended before the long-term health benefits of participation in an intensive lifestyle weight loss treatment could be observed.
36. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8.
37. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73.
38. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.
39. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37 Suppl 1:S14–80.
40. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.
41. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S65–7.
42. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.
43. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30(6):1374–83.
44. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–75.
45. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–654.
46. Espeland MA, Lewis CE, Bahnson J, et al. Impact of weight loss on ankle-brachial index and interartery blood pressures. Obesity (Silver Spring). 2014;22(4):1032–41.
47. Clark CE, Campbell JL, Powell RJ. The interarm blood pressure difference as predictor of cardiovascular events in patients with hypertension in primary care: cohort study. J Hum Hypertens. 2007;21(8):633–8.
48. Clark CE, Campbell JL, Powell RJ, Thompson JF. The inter-arm blood pressure difference and peripheral vascular disease: cross-sectional study. Fam Pract. 2007;24(5):420–6.
49. Clark CE, Campbell JL, Evans PH, Millward A. Prevalence and clinical implications of the inter-arm blood pressure difference: a systematic review. J Hum Hypertens. 2006;20(12):923–31.
50. Redmon JB, Bertoni AG, Connelly S, et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2010;33(6):1153–8.
51. US Department of Health and Human Services. Physical activity and health: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
52. Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med. 2005;165(18):2114–20.
53. Kesaniemi YK, Danforth Jr E, Jensen MD, Kopelman PG, Lefebvre P, Reeder BA. Dose-response issues concerning physical activity and health: an evidence-based symposium. Med Sci Sports Exerc. 2001;33(6 Suppl):S351–8.
54. Blair SN, Kohl 3rd HW, Barlow CE, Paffenbarger Jr RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA. 1995;273(14):1093–8.
55. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–27.
56. Sigal RJ, Kenny GP, Boule NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147(6):357–69.
57. Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2010;304(20):2253–62.
58. Gibbs BB, Brancati FL, Chen H, et al. Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. Eur J Prev Cardiol. 2014;21(5):608–17.
59. Belalcazar LM, Lang W, Haffner SM, et al. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. J Lipid Res. 2012;53(12):2726–33.
60. Belalcazar LM, Ballantyne CM, Lang W, et al. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011;31(7):1689–95.
61. Belalcazar LM, Reboussin DM, Haffner SM, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33(11):2297–303.
62. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the Look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012;20(7):1511–8.
63. Belalcazar LM, Haffner SM, Lang W, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013;21(5):944–50.
64. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489–96. Type 2 diabetes is thought to be an irreversible condition. However, a significant proportion of participants in the ILI achieved partial or complete remission of type 2 diabetes at year 1 and these results remained at year 4. Improvements in blood glucose control are likely to reduce the risk of microvascular complications and subsequently reduce the risk for CVD mortality.
65. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75(14):894–903.
66. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–13.
67. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ. 2002;324(7353):1577–80.
68. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–12.
69. Hood RC. It can be done. Diabetes Care. 2003;26(12):3359–60.
70. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30(10):2478–83.
71. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.
72. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–7.
73. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol. 2005;99(4):1592–9.
74. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med. 2002;162(8):893–900.
75. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005;172(11):1447–51.
76. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2010;182(2):269–77.
77. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6(8):e1000132.
78. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31(8):1071–8.
79. Rice TB, Foster GD, Sanders MH, et al. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. Sleep. 2012;35(9):1293–8.
80. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641–649A.
81. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66(3):305–15.
82. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66(6):814–22.
83. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28(6):1339–45.
84. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2–8.
85. Rubin RR, Gaussoin SA, Peyrot M, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581–9.
86. Rubin RR, Peyrot M, Gaussoin SA, et al. Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care. 2013;36(5):1088–94.
87. The Look AHEAD Research Group. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544–53.
88. Faulconbridge LF, Wadden TA, Rubin RR, et al. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity (Silver Spring). 2012;20(4):783–93.
89. Rejeski WJ, Bray GA, Chen SH, et al. Aging and physical function in type 2 diabetes: 8 years of an intensive lifestyle intervention. J Gerontol A Biol Sci Med Sci. 2014.
90. Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619–27.